Sunday 11 October 2026
Export all RLYB data to Excel Powerpack
Rallybio Corporation
RLYB Healthcare Biotechnology
In the quarter to June 2026, revenue was flat, EPS grew 535.2% and free cash flow grew 648.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
17.02
0.03
+0.18%
Follow RLYB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(21.17%) | (15.01%) | (14.98%) | 64.86% | |
| (19.32%) | (13.77%) | (13.90%) | 61.12% | ||
ROIC |
(643.67%) | (641.77%) | (576.66%) | (1,052.03%) | |
Return on Tangible Assets |
(22.81%) | (15.74%) | (15.83%) | 48.62% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(6.21) | (5.30) | (4.85) | 4.69 | |
Free Cash Flow |
(35.00) | (29.81) | (27.59) | 26.71 | |
| Other line items | |||||
Cash ROIC |
(28.60%) | (26.46%) | (28.42%) | 14.26% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.03) | |
Research and Development Expense of Revenue |
3,460.98% | 2,284.03% | 1,951.40% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2,315.58% | 1,669.58% | 1,893.01% | 0.00% | |
Share Based Compensation of Revenue |
964.84% | 619.35% | 471.79% | 0.00% | |
Operating CF/Net income |
2.47 | 3.32 | 3.53 | 0.59 | |
Depreciation/Fixed assets |
(25.88) | (20.91) | (17.35) | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.12 | 0.15 | 0.15 | 0.00 | |
Operating CF per Share |
(6.21) | (5.30) | (4.85) | 4.69 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates